JP7399934B2 - 免疫原性複合体の改良 - Google Patents

免疫原性複合体の改良 Download PDF

Info

Publication number
JP7399934B2
JP7399934B2 JP2021500060A JP2021500060A JP7399934B2 JP 7399934 B2 JP7399934 B2 JP 7399934B2 JP 2021500060 A JP2021500060 A JP 2021500060A JP 2021500060 A JP2021500060 A JP 2021500060A JP 7399934 B2 JP7399934 B2 JP 7399934B2
Authority
JP
Japan
Prior art keywords
carrier polypeptide
antigen
immunogenic
pharmaceutical composition
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021500060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530468A (ja
JPWO2020009993A5 (https=
JP2021530468A5 (https=
Inventor
ジェファリー・フェアマン
ジョン・ハインリクス
ウェイ・チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxcyte Inc
Original Assignee
Vaxcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxcyte Inc filed Critical Vaxcyte Inc
Publication of JP2021530468A publication Critical patent/JP2021530468A/ja
Publication of JPWO2020009993A5 publication Critical patent/JPWO2020009993A5/ja
Publication of JP2021530468A5 publication Critical patent/JP2021530468A5/ja
Priority to JP2023206041A priority Critical patent/JP7796716B2/ja
Application granted granted Critical
Publication of JP7399934B2 publication Critical patent/JP7399934B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
JP2021500060A 2018-07-04 2019-07-01 免疫原性複合体の改良 Active JP7399934B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023206041A JP7796716B2 (ja) 2018-07-04 2023-12-06 免疫原性複合体の改良

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693981P 2018-07-04 2018-07-04
US62/693,981 2018-07-04
PCT/US2019/040131 WO2020009993A1 (en) 2018-07-04 2019-07-01 Improvements in immunogenic conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023206041A Division JP7796716B2 (ja) 2018-07-04 2023-12-06 免疫原性複合体の改良

Publications (4)

Publication Number Publication Date
JP2021530468A JP2021530468A (ja) 2021-11-11
JPWO2020009993A5 JPWO2020009993A5 (https=) 2022-07-08
JP2021530468A5 JP2021530468A5 (https=) 2022-07-08
JP7399934B2 true JP7399934B2 (ja) 2023-12-18

Family

ID=67439412

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500060A Active JP7399934B2 (ja) 2018-07-04 2019-07-01 免疫原性複合体の改良
JP2023206041A Active JP7796716B2 (ja) 2018-07-04 2023-12-06 免疫原性複合体の改良

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023206041A Active JP7796716B2 (ja) 2018-07-04 2023-12-06 免疫原性複合体の改良

Country Status (16)

Country Link
EP (2) EP3817775B1 (https=)
JP (2) JP7399934B2 (https=)
KR (1) KR20210042904A (https=)
CN (1) CN112543649B (https=)
AU (2) AU2019299836B2 (https=)
BR (1) BR112020026899A2 (https=)
CA (1) CA3105361A1 (https=)
DK (1) DK3817775T3 (https=)
EA (1) EA202190168A1 (https=)
ES (1) ES2989087T3 (https=)
IL (1) IL279855B2 (https=)
MX (1) MX2020014118A (https=)
PH (1) PH12020552282A1 (https=)
SG (1) SG11202012905PA (https=)
WO (1) WO2020009993A1 (https=)
ZA (1) ZA202100761B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022035816A1 (en) * 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
EP4200268A4 (en) 2020-08-19 2024-10-16 Vaxcyte, Inc. CARRIER PROTEIN POLYSACCHARIDE CONJUGATION PROCESS
GB202108648D0 (en) * 2021-06-17 2021-08-04 Inst De Medicina Molecular Joaeo Lobo Antunes CRM197 protein carrier

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520761A (ja) 2005-12-22 2009-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2012521403A (ja) 2009-03-24 2012-09-13 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
JP2014518061A (ja) 2011-06-01 2014-07-28 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
JP2015501329A (ja) 2011-11-07 2015-01-15 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
JP2015529208A (ja) 2012-08-31 2015-10-05 ストロ バイオファーマ インコーポレーテッド アジド基を含む修飾アミノ酸
US20160257946A1 (en) 2013-10-11 2016-09-08 Sutro Biopharma, Inc. NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PARA-METHYLAZIDO-L-PHENYLALANINE
JP2017504661A (ja) 2014-01-21 2017-02-09 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖体およびそれらのコンジュゲート
JP2020504760A (ja) 2016-12-30 2020-02-13 ストロバックス・インコーポレイテッドＳｕｔｒｏｖａｘ， Ｉｎｃ． 非天然アミノ酸とのポリペプチド抗原接合体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0375778B1 (en) 1987-06-19 1993-09-08 Terumo Kabushiki Kaisha Medical instrument and production thereof
ATE109008T1 (de) 1988-02-01 1994-08-15 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
JP2001190665A (ja) 2000-01-14 2001-07-17 Terumo Corp シリンジ
WO2001070763A1 (en) * 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2604363C (en) 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ562719A (en) 2005-04-08 2008-12-24 Wyeth Corp Separation of contaminants from streptococcus pneumoniae polysaccharide by pH manipulation
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ598367A (en) * 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
PT2074221E (pt) 2006-10-10 2010-09-06 Wyeth Llc Métodos melhorados para a separação de polissacáridos tipo 3 de streptococcus pneumoniae
PT2129693T (pt) 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
CN102307905B (zh) * 2008-12-10 2015-11-25 斯克利普斯研究院 利用化学反应性非天然氨基酸产生载体-肽偶联物
IT1398927B1 (it) * 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2011212183A (ja) 2010-03-31 2011-10-27 Terumo Corp プレフィルドシリンジ
WO2014053521A2 (en) 2012-10-02 2014-04-10 Novartis Ag Nonlinear saccharide conjugates
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014102265A1 (en) * 2012-12-27 2014-07-03 Glycovaxyn Ag Methods and compositions relating to crm197
ITMI20130142A1 (it) * 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
AU2015210674B2 (en) 2014-01-31 2017-08-24 Fina Biosolutions, Llc Expression and purification of CRM197 and related proteins
AR101455A1 (es) * 2014-08-05 2016-12-21 Glaxosmithkline Biologicals Sa Molécula portadora
EP4488286A3 (en) * 2016-03-31 2025-04-02 Pogona, Llc Saccharide-polypeptide conjugate compositions and methods of use thereof
BR112019006278A2 (pt) * 2016-09-30 2019-07-02 Biological E Limited composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520761A (ja) 2005-12-22 2009-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP2012521403A (ja) 2009-03-24 2012-09-13 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ
JP2014518061A (ja) 2011-06-01 2014-07-28 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
JP2015501329A (ja) 2011-11-07 2015-01-15 ノバルティス アーゲー ｓｐｒ００９６抗原およびｓｐｒ２０２１抗原を含むキャリア分子
JP2015529208A (ja) 2012-08-31 2015-10-05 ストロ バイオファーマ インコーポレーテッド アジド基を含む修飾アミノ酸
US20160257946A1 (en) 2013-10-11 2016-09-08 Sutro Biopharma, Inc. NON-NATURAL AMINO ACID tRNA SYNTHETASES FOR PARA-METHYLAZIDO-L-PHENYLALANINE
WO2015110941A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015110940A2 (en) 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
JP2017504661A (ja) 2014-01-21 2017-02-09 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖体およびそれらのコンジュゲート
JP2020504760A (ja) 2016-12-30 2020-02-13 ストロバックス・インコーポレイテッドＳｕｔｒｏｖａｘ， Ｉｎｃ． 非天然アミノ酸とのポリペプチド抗原接合体

Also Published As

Publication number Publication date
EP3817775B1 (en) 2024-09-04
CN112543649A (zh) 2021-03-23
KR20210042904A (ko) 2021-04-20
EP4483896A3 (en) 2025-04-02
IL279855A (en) 2021-03-01
JP2021530468A (ja) 2021-11-11
CN112543649B (zh) 2026-03-31
WO2020009993A1 (en) 2020-01-09
CA3105361A1 (en) 2020-01-09
EP4483896A2 (en) 2025-01-01
ES2989087T3 (es) 2024-11-25
SG11202012905PA (en) 2021-01-28
ZA202100761B (en) 2025-05-28
IL279855B1 (en) 2025-09-01
IL279855B2 (en) 2026-01-01
MX2020014118A (es) 2021-06-18
DK3817775T3 (da) 2024-09-16
AU2019299836B2 (en) 2025-08-21
PH12020552282A1 (en) 2021-06-28
EP3817775A1 (en) 2021-05-12
JP2024037805A (ja) 2024-03-19
EA202190168A1 (ru) 2021-06-07
AU2025256067A1 (en) 2025-11-13
BR112020026899A2 (pt) 2021-03-30
AU2019299836A1 (en) 2021-02-25
JP7796716B2 (ja) 2026-01-09

Similar Documents

Publication Publication Date Title
JP7796716B2 (ja) 免疫原性複合体の改良
CN103209708B (zh) 免疫原性组合物
TWI756893B (zh) 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
RU2634405C2 (ru) Иммуногенная композиция
JP2022105155A (ja) 多糖類－タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
CN102596254B (zh) 金黄色葡萄球菌5型和8型荚膜多糖的偶联
IE58977B1 (en) Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such plysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
CN106102770A (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
CN108064174A (zh) 抗原的载体分子
JP2018522978A (ja) 免疫原性組成物
JP2026071217A (ja) 免疫原性複合体の改良
HK40121270A (en) Improvements in immunogenic conjugates
EA048282B1 (ru) Усовершенствования в иммуногенных конъюгатах
HK40050310B (en) Improvements in immunogenic conjugates
HK40050310A (en) Improvements in immunogenic conjugates
HK40074022B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40117919A (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40021072B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
CN120265317A (zh) 包含经缀合的荚膜糖抗原的免疫原性组合物及其用途
HK1229726B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231206

R150 Certificate of patent or registration of utility model

Ref document number: 7399934

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150